Ask, Advise to quit and Assess are the steps in approaching patients regarding smoking cessation.
All patients should be asked if they use tobacco and should have their tobacco status documented on a regular basis.
Patient with nicotine dependence is characterized by smoking within 30 minutes of waking, consuming >10 cigarettes/day and had withdrawal symptoms in previous attempts of quitting smoking.
Smokers should be strongly urged to quit at every physician encounter.
Advice should be clear, personalized, supportive and non-judgmental.
Determine the willingness of smoker to make a quit attempt.
While adding varenicline to weekly counselling for smoking cessation did not improve abstinence rates among adolescent smokers at the end of treatment, it may promote earlier abstinence and sustained response to varenicline post-treatment, a study finds.
Dr Ong Kian Chung, a respiratory specialist at the KC Ong Chest & Medical Clinic, Mount Elizabeth Medical Centre, Singapore spoke on the evils of tobacco use and how clinicians can help in smoking cessation.
Over two-thirds of respondents who try the first cigarette progress to daily smoking, at least temporarily, according to a meta-analysis of large-scale national surveys, demonstrating “the remarkable hold that cigarettes can establish after a single experience” ─ in the words of study senior co-author Professor Peter Hajek.
A study finds no evidence that using pharmaceutical aids alone for smoking cessation helps improve the chances of successful quitting despite promising results in previous randomized trials and routine prescription of such drugs to help quit smoking.
First-line treatment with the epidermal growth factor receptor tyrosine kinase inhibitor (EGFR TKI) dacomitinib demonstrated persistent survival benefit in patients with EGFR-positive advanced non-small cell lung cancer (NSCLC), according to updated results from the phase III ARCHER 1050* trial.
Sequential treatment with afatinib followed by osimertinib enables prolonged chemotherapy-free treatment while sustaining clinical benefit in patients with EGFR-mutation positive (EGFR+) non-small–cell lung cancer (NSCLC) who acquire T790M mutation, according to the real-world retrospective GioTag study presented at ESMO Asia 2018.